Lupin Receives US FDA EIR for Nagpur Injectable Facility

🧪

has received the Establishment Inspection Report (EIR) from the US FDA for its injectable manufacturing facility in Nagpur, with a Voluntary Action Indicated (VAI) classification following the September inspection, reaffirming regulatory compliance at the plant.